ClinicalTrials.gg
CompletedNCT04046549Updated Dec 27, 2024Results posted

A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

A Phase 2 interventional study of Belatacept and VIB4920 in Allografts, Rejection; Transplant, Kidney and Transplant Rejection, sponsored by Amgen. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Amgen · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of dual costimulation blockade with VIB4920 in combination of belatacept in adult male or female recipients of a renal allograft from a deceased, living unrelated or human leukocyte antigen (HLA) non-identical living related donor.

Read the detailed description

Study with completed results acquired from Horizon in 2024.

02

Conditions studied

  • Allografts
  • Rejection; Transplant, Kidney
  • Transplant Rejection
  • Kidney Transplantation

Keywords

  • Renal allograft dysfunction
  • Cell-mediated rejection
  • Antibody mediated rejection
  • Immunosuppression
  • Acute rejection
  • VIB4920
  • MEDI4920
  • Belatacept
  • Thymoglobulin
  • Methylprednisolone
  • Corticosteroids
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recipients of a first renal transplant from standard criteria deceased, living unrelated or HLA non-identical living related donor.
  • Recipients who are at low immunologic risk:

    1. No donor specific antibodies (DSA), and
    2. Negative cross-match testing.
  • Recipients with up to date vaccination as per local immunization schedules.
  • Male and female participants who agree to follow protocol defined methods.

Exclusion criteria

Exclusion Criteria:

  • Participants receiving an allograft from an ABO-incompatible donor.
  • Participants treated with systemic drug therapy for more than a total of 2 weeks within 24 weeks prior to form signature.
  • Participants who have undergone lymphodepleting therapy.
  • Participants with medical history of confirmed venous thromboembolism, arterial thrombosis, coagulopathy or known disorders.
  • Participants with risk factors for venous thromboembolism or arterial thrombosis, prothrombotic status.
  • Participants requiring treatment with antithrombotic drugs (clopidogrel, prasugrel, warfarin, others).
  • Participants requiring long-term systemic anticoagulation after transplantation, which would interfere with obtaining .
  • Participants with any to kidney biopsy.
  • Cytomegalovirus (CMV)-seronegative recipients of a CMV-seropositive donor kidney, or unknown CMV serostatus.
  • Epstein-Barr virus (EBV)-seronegative or with unknown EBV serostatus.
  • Receipt of live (attenuated) vaccine within the 4 weeks before screening.
  • Participants with high potential of graft loss due to recurrence of underlying kidney disease.
  • Prior solid organ transplant or potential to require a concurrent organ or cell transplant.
  • Previous treatment with belatacept and cluster of differentiation 40 (0) or anti-CD40L agents.
  • Use of B cell depleting therapy, non-depleting B cell directed therapy e.g., belimumab or abatacept within 1 year prior to enrolment.
  • At screening blood tests any of the following:

    1. (AST) > 2.5 × (ULN)
    2. Alanine aminotransferase (ALT) > 2.5 × ULN
    3. Alkaline phosphatase (ALP) > 2.5 × ULN
    4. Total (TBL) > 2 × ULN
    5. \< 75 g/L
    6. Neutrophils \< 1.5 × 10\^9/L
    7. Platelets \< 100 × 10\^9/L
  • Participants with severe systemic infections, current or within the 2 weeks prior to transplant surgery.
  • Positive test for chronic infection at screening or within the last 12 months.
  • Positive test for virus antibody at screening or within the last 12 months.
  • Positive test for human immunodeficiency viruses antibody at screening or within the last 12 months.
  • History of or active tuberculosis (TB), or a positive QuantiFERON®-TB Gold test at screening, unless previously treated for latent tuberculosis.
  • History of cancer, except as follows:

    1. In situ carcinoma of the cervix treated with apparent success with curative therapy > 12 months prior to screening; or
    2. Cutaneous basal cell or squamous cell carcinoma treated with apparent success with curative therapy.
  • Lactating or pregnant females.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Belatacept+VIB4920

    Participants will be admitted to the transplant center for the administration of VIB4920 and belatacept (with Thymoglobulin and corticosteroids) and will be discharged on Day 3/4 at the discretion of the investigator. Participants will return to the study center to receive study drugs (VIB4920 and /or belatacept) weekly for 2 visits, then every 2 weeks for 5 visits, and then monthly for 9 visits for safety monitoring.

    Drug: Belatacept · Drug: VIB4920 · Drug: Thymoglobulin · Drug: Methylprednisolone

Interventions

  • Protocol versions 1 through 4: Belatacept 10 mg/kg by intravenous (IV) infusion on post-op Day 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), and at the end of Weeks 2, 4, 8 and 12; then 5 mg/kg IV every 4 weeks from Week 16 to Week 48.

  • Protocol versions 1 and 2: VIB4920 1500 mg by IV infusion on post-op Days 1 and 14, and at the end of Weeks 4, 6, 8 and 10; then 1500 mg every 4 weeks from Week 12 to Week 48. Protocol versions 3 and 4: VIB4920 1500 mg by IV infusion on post-op Days 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), Week 2, and at the end of Weeks 4, 6, 8, and 10; then 1500 mg every 4 weeks from Week 12 to Week 48.

  • Protocol versions 1 and 2: Thymoglobulin 3.0 mg/kg by intravenous (IV) infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0) (1 dose). Protocol versions 3 and 4: Thymoglobulin 1.5 mg/kg by intravenous infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0), prior to VIB4920+belatacept infusion on post-op Day 1, on post-op Day 2, and prior to VIB4920+belatacept infusion on post-op Day 3 or 4.

  • Protocol versions 1 and 2: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, and 6. Protocol versions 3 and 4: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, 6 and 7. Participants may be tapered to at least 20 mg per day on Day 8, to at least 10 mg per day on Day 15, and to at least 5 mg per day on Day 22. Discontinuation of prednisone following the post-op Day 28 visit.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR) of Grade 1A or Higher, Graft Loss or Death at Week 24

    Histological grading of acute allograft rejection from biopsy specimens was based on Banff criteria 2017. Grade IA: Moderate tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade IB: Severe tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade II. Arterial intimal fibrosis with mononuclear cell inflammation, formation of neointima.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR) of Grade 1A or Higher, Graft Loss or Death at Weeks 12 and 48

    Histological grading of acute allograft rejection from biopsy specimens was based on Banff criteria 2017. Grade IA: Moderate tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade IB: Severe tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade II. Arterial intimal fibrosis with mononuclear cell inflammation, formation of neointima.

    Time frame: Weeks 12 and 48

  2. Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR), Graft Loss, Death or Loss to Follow-up (LTFU)

    Histological grading of acute allograft rejection from biopsy specimens was based on Banff criteria 2017. Grade IA: Moderate tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade IB: Severe tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade II. Arterial intimal fibrosis with mononuclear cell inflammation, formation of neointima.

    Time frame: Week 12, 24, 48

  3. Percentage of Participants With Antibody-Mediated Rejection

    The diagnosis of antibody-mediated rejection was based on Banff criteria 2017 - a set of standardized guidelines used by pathologists and clinicians to diagnose and classify rejection based on specific features observed in biopsy samples from the transplanted organ, such as the presence of certain types of immune cells, inflammation, and injury patterns.

    Time frame: Week 12, 24, 48

  4. Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR)

    Histological grading of acute allograft rejection from biopsy specimens was based on Banff criteria 2017. Grade IA: Moderate tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade IB: Severe tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade II. Arterial intimal fibrosis with mononuclear cell inflammation, formation of neointima. tBPAR was defined as a BPAR which was treated with anti-rejection therapy.

    Time frame: Week 12, 24, 48

  5. Percentage of Participants With Biopsy Proven Acute Rejection (BPAR)

    Histological grading of acute allograft rejection from biopsy specimens was based on Banff criteria 2017. Grade IA: Moderate tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade IB: Severe tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade II. Arterial intimal fibrosis with mononuclear cell inflammation, formation of neointima.

    Time frame: Week 12, 24, 48

  6. Percentage of Participants With Treated Acute Rejections

    Acute rejections, per clinical judgement of the investigator followed by confirmatory biopsy, were treated with bolus methylprednisolone (other corticosteroids were acceptable at an equivalent dose) according to local practice.

    Time frame: Week 12, 24, 48

  7. Percentage of Participants With De Novo Donor-specific Antibodies (dnDSA)

    Serum samples were collected for de novo donor-specific antibodies (dnDSA) using solid phase (bead-based) assays.

    Time frame: Week 12, 24, 48

07

Results

Posted Oct 10, 2023

Participant flow

Participant flow — Overall Study
MilestoneBelatacept+VIB4920
Started23
Enrolled prior to protocol v3.03
Completed13
Not completed10
Withdrew: Adverse event1
Withdrew: Physician decision1
Withdrew: Withdrawal by subject3
Withdrew: Other, not specified5

Outcome measures

PrimaryPercentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR) of Grade 1A or Higher, Graft Loss or Death at Week 24

Histological grading of acute allograft rejection from biopsy specimens was based on Banff criteria 2017. Grade IA: Moderate tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade IB: Severe tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade II. Arterial intimal fibrosis with mononuclear cell inflammation, formation of neointima.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR) of Grade 1A or Higher, Graft Loss or Death at Week 24
percentage of participantsBelatacept+VIB4920
Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR) of Grade 1A or Higher, Graft Loss or Death at Week 2425.0 (12.7 to 41.5)
SecondaryPercentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR) of Grade 1A or Higher, Graft Loss or Death at Weeks 12 and 48

Histological grading of acute allograft rejection from biopsy specimens was based on Banff criteria 2017. Grade IA: Moderate tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade IB: Severe tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade II. Arterial intimal fibrosis with mononuclear cell inflammation, formation of neointima.

Time frame:
Weeks 12 and 48
Reported as:
Number · percentage of participants
Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR) of Grade 1A or Higher, Graft Loss or Death at Weeks 12 and 48
percentage of participantsBelatacept+VIB4920
Week 1225.0 (12.7 to 41.5)
Week 4825.0 (12.7 to 41.5)
SecondaryPercentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR), Graft Loss, Death or Loss to Follow-up (LTFU)

Histological grading of acute allograft rejection from biopsy specimens was based on Banff criteria 2017. Grade IA: Moderate tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade IB: Severe tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade II. Arterial intimal fibrosis with mononuclear cell inflammation, formation of neointima.

Time frame:
Week 12, 24, 48
Reported as:
Number · percentage of participants
Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR), Graft Loss, Death or Loss to Follow-up (LTFU)
percentage of participantsBelatacept+VIB4920
Week 1225.0 (12.7 to 41.5)
Week 2425.0 (12.7 to 41.5)
Week 4825.0 (12.7 to 41.5)
SecondaryPercentage of Participants With Antibody-Mediated Rejection

The diagnosis of antibody-mediated rejection was based on Banff criteria 2017 - a set of standardized guidelines used by pathologists and clinicians to diagnose and classify rejection based on specific features observed in biopsy samples from the transplanted organ, such as the presence of certain types of immune cells, inflammation, and injury patterns.

Time frame:
Week 12, 24, 48
Reported as:
Number · percentage of participants
Percentage of Participants With Antibody-Mediated Rejection
percentage of participantsBelatacept+VIB4920
Week 1210.0 (2.7 to 24.5)
Week 2410.0 (2.7 to 24.5)
Week 4815.0 (5.6 to 30.4)
SecondaryPercentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR)

Histological grading of acute allograft rejection from biopsy specimens was based on Banff criteria 2017. Grade IA: Moderate tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade IB: Severe tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade II. Arterial intimal fibrosis with mononuclear cell inflammation, formation of neointima. tBPAR was defined as a BPAR which was treated with anti-rejection therapy.

Time frame:
Week 12, 24, 48
Reported as:
Number · percentage of participants
Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR)
percentage of participantsBelatacept+VIB4920
Week 1225.0 (12.7 to 41.5)
Week 2425.0 (12.7 to 41.5)
Week 4825.0 (12.7 to 41.5)
SecondaryPercentage of Participants With Biopsy Proven Acute Rejection (BPAR)

Histological grading of acute allograft rejection from biopsy specimens was based on Banff criteria 2017. Grade IA: Moderate tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade IB: Severe tubulitis and at least moderate total cortical inflammation and at least moderate scarred cortical inflammation and other known causes ruled out. Grade II. Arterial intimal fibrosis with mononuclear cell inflammation, formation of neointima.

Time frame:
Week 12, 24, 48
Reported as:
Number · percentage of participants
Percentage of Participants With Biopsy Proven Acute Rejection (BPAR)
percentage of participantsBelatacept+VIB4920
Week 1225.0 (12.7 to 41.5)
Week 2425.0 (12.7 to 41.5)
Week 4825.0 (12.7 to 41.5)
SecondaryPercentage of Participants With Treated Acute Rejections

Acute rejections, per clinical judgement of the investigator followed by confirmatory biopsy, were treated with bolus methylprednisolone (other corticosteroids were acceptable at an equivalent dose) according to local practice.

Time frame:
Week 12, 24, 48
Reported as:
Number · percentage of participants
Percentage of Participants With Treated Acute Rejections
percentage of participantsBelatacept+VIB4920
Week 1225.0 (12.7 to 41.5)
Week 2425.0 (12.7 to 41.5)
Week 4830.0 (16.7 to 46.7)
SecondaryPercentage of Participants With De Novo Donor-specific Antibodies (dnDSA)

Serum samples were collected for de novo donor-specific antibodies (dnDSA) using solid phase (bead-based) assays.

Time frame:
Week 12, 24, 48

Results for this outcome have not been posted.

Adverse events

Collected over All-Cause Mortality: From written informed consent signature (Day -28 to -1) and the end of the safety follow-up 60 weeks (up to 64 weeks) Adverse Events: From first dose of study drug until the end of treatment + 12 weeks (up to 60 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belatacept+VIB49200/23 (0%)10/23 (43.5%)20/23 (87%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventBelatacept+VIB4920
Post procedural urine leakInjury, poisoning and procedural complications2/23
IleusGastrointestinal disorders1/23
Cholecystitis acuteHepatobiliary disorders1/23
Kidney transplant rejectionImmune system disorders1/23
BacteraemiaInfections and infestations1/23
Clostridium difficile infectionInfections and infestations1/23
Diabetic foot infectionInfections and infestations1/23
Urinary tract infectionInfections and infestations1/23
UrosepsisInfections and infestations1/23
Arteriovenous fistula site complicationInjury, poisoning and procedural complications1/23
Most frequent other events
Showing 10 of 14
Most frequent other events
EventBelatacept+VIB4920
COVID-19Infections and infestations5/23
AnaemiaBlood and lymphatic system disorders4/23
LeukopeniaBlood and lymphatic system disorders4/23
BK virus infectionInfections and infestations4/23
HypophosphataemiaMetabolism and nutrition disorders4/23
ArthralgiaMusculoskeletal and connective tissue disorders3/23
HeadacheNervous system disorders3/23
NeutropeniaBlood and lymphatic system disorders2/23
Urinary tract infectionInfections and infestations2/23
Procedural painInjury, poisoning and procedural complications2/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)Belatacept+VIB4920
Mean47.7 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Belatacept+VIB4920
Female4
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Belatacept+VIB4920
Hispanic or Latino8
Not Hispanic or Latino15
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Belatacept+VIB4920
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White16
More than one race0
Unknown or Not Reported5
08

Study locations

4 sites
  • Keck Medical Center of USC
    Los Angeles, California 90033, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Duke University School of Medicine
    Durham, North Carolina 27710, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Jul 2022, 32 months.

Results were first posted in Oct 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2019
First posted
Aug 6, 2019
StartActual
Oct 30, 2019
Primary completionActual
Jul 18, 2022
CompletionActual
Mar 22, 2023
Results first posted
Oct 10, 2023
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04046549
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 6, 2019
Start date
Oct 30, 2019
Primary completion
Jul 18, 2022
Completion
Mar 22, 2023
Results posted
Oct 10, 2023
Last update
Dec 27, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dazodalibep

Start the discussion